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RESPONSE TO LETTER TO THE EDITOR: 26 
We thank Dr Turner and Pr. Kerber for their interest in our article on the association between menopausal 27 
hormone therapy (MHT) and reduced android and visceral adiposity 1. Their letter brings additional 28 
insight to the results of our study, providing important data from animal studies, which corroborate our 29 
findings and suggest underlying pathophysiological mechanisms.  30 
In our article, we considered the benefits of MHT to derive from the direct effect of estrogen on adipose 31 
tissue, given the absence of significant differences between groups regarding potential intermediary 32 
factors such as caloric intake and physical activity. Nevertheless, as acknowledged in the article’s 33 
discussion, the assessment of confounding factors was only partial, thus preventing us from drawing 34 
definitive conclusions. In their letter, Turner et al. highlight an elegant study in ovariectomized rodents, 35 
which revealed that 17β-estradiol supplementation restored normal lipolytic function, in contrast to 36 
physical exercise alone 2. These data imply that MHT in our study may have reduced android fat and 37 
visceral adipose tissue via alteration of basic lipolytic rate.  38 
The authors attribute the absence of residual effect in past users to the eventual down-regulation of 39 
estrogen receptor (ER) and subsequent loss-of-function of important estrogen-associated metabolic 40 
pathways. Though this speculation remains plausible, we would like to stress that the response of the 41 
target organs following MHT withdrawal seems to be tissue-specific, given our previous findings of a less 42 
pronounced rebound effect on bone density and microarchitecture 3. 43 
Based on several animal studies, Turner et al. support the theory of ‘euestrogenemia’ 4 arguing in favor of 44 
the critical window hypothesis to explain that the estrogen receptor has distinct responses according to the 45 
timing of estrogen administration. Extrapolating these data to humans, we would expect that early MHT 46 
use would have more favorable outcomes, as suggested by subgroup analysis of the Women’s Health 47 
Initiative 5. More recently, the most convincing clinical data in favor of this hypothesis come from the 48 
ELITE randomized clinical trial (RCT), which showed reduced carotid-artery intima-media thickness after 49 
6 months of MHT selectively in early (< 6 years) compared with late post-menopausal (> 10 years) 50 
women 6. In OsteoLaus, however, we were able to detect a benefit for BMI, android fat and VAT despite a 51 
broader age of studied population (50-80 years). A possible explanation is that MHT duration was 52 
relatively long (12.2 ± 8.8 years) for a mean age of 62.6 ± 6.7 years in current users. It is likely that MHT 53 
was started early after menopause in the majority of the participants, who fulfilled, thus, the criteria of 54 
‘eustrogenemia’. 55 
In the light of the aforementioned evidence, we agree with Turner et al that the findings of our 56 
observational study should encourage further research to explore the optimal use of MHT.  57 
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